ReviewJournal of anesthesia and translational medicine2025
Remimazolam in anesthesia and sedation: A narrative review.
Review in Journal of anesthesia and translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Optimal prophylaxis for perioperative drug-induced delayed neurocognitive recovery: a Bayesian network meta-analysis of 18 interventions with mechanism-based stratification.Frontiers in pharmacology · 2026Pooled it
- Age-Stratified EDDrug design, development and therapy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Remimazolam, an innovative sedative, provides a rapid onset and quick recovery by being rapidly hydrolyzed into pharmacologically inactive CNS7054 via ubiquitous nonspecific esterases. Its pharmacokinetic characteristics (high clearance rate, small steady-state volume of distribution, short terminal half-life, and no tissue accumulation) further lay the foundation for clinical application. Compared with traditional sedative drugs, the prominent innovations of this drug are reflected in three aspects: first, it has less impact on the respiratory and circulatory systems, with stable hemodynamics and a low incidence of discomfort at the administration site; second, its sedative effect can be specifically antagonized by flumazenil, allowing for more flexible safety regulation; third, it shows excellent safety and effectiveness in special populations such as elderly patients and those with comorbid cardiovascular diseases. Clinical evidence shows that remimazolam is more effective than similar drugs in scenarios such as gastrointestinal endoscopy, operating rooms, and ICUs. Its reliable performance in special populations further supports its value as a sedative that combines innovation with clinical practicality and holds broad application prospects. This review aims to systematically elaborate on the pharmacological properties and clinical application value of remimazolam, a new benzodiazepine derivative, and provide references for its standardized use in various diagnostic and therapeutic scenarios and special populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.